FACT / 30/09/2025 by TLJ

Eli Lilly’s Blockbuster Drug Growth in Q3 2023

  • N ews (3)
  • N ews (3)

In the third quarter of 2023, Eli Lilly and Company reported revenue of $9.5 billion, a remarkable 37% year-over-year increase, driven by blockbuster drugs like Mounjaro and Zepbound in the diabetes and obesity markets. Net income reached $2.1 billion, reflecting strong demand and pricing power. Mounjaro, a GLP-1 receptor agonist, generated $1.4 billion in sales, capturing 20% of the U.S. diabetes market and positioning Lilly as a leader in the $100 billion obesity treatment space. The company’s pipeline, including phase 3 trials for new indications, supports projected revenue growth of 25% annually through 2027, with oncology and Alzheimer’s drugs adding diversification.

  • Share:

by EDWARD COLLINS 30/09/2025 30

Fund Rotation Signals Overvaluation

The Saudi sovereign fund’s focus on Unit....

by MARIA CUNNINGAM 30/09/2025 30

Insider Buying Signals Pipeline Confidence​

Insider buying of $4 million, including $1 million by the CEO

by ROBERT GRASS 30/09/2025 26

Analyst Upgrades Boost Outlook​

A positive deal with a $125 target from Raymond

by LAUREN HUGHES 30/09/2025 24

Novo’s Value Outshines Lilly

Novo Nordisk’s 52-week lows at $67 reflect fears.....

by LUIGI CAVALIERI 30/09/2025 23

Healthcare’s Undervalued Opportunity

Healthcare is the most undervalued sector, with insider buying

by NATALIE SPENCER 30/09/2025 21

Supply Constraints Favor Competitors

Novo’s P/E below its 10-year average and strong

by MARIA CUNNINGAM 30/09/2025 30

Insider Buying Signals Pipeline Confidence​

Insider buying of $4 million, including $1 million by the CEO

by ROBERT GRASS 30/09/2025 26

Analyst Upgrades Boost Outlook​

A positive deal with a $125 target from Raymond

by LUIGI CAVALIERI 30/09/2025 23

Healthcare’s Undervalued Opportunity

Healthcare is the most undervalued sector, with insider buying

by EDWARD COLLINS 30/09/2025 30

Fund Rotation Signals Overvaluation

The Saudi sovereign fund’s focus on Unit....

by LAUREN HUGHES 30/09/2025 24

Novo’s Value Outshines Lilly

Novo Nordisk’s 52-week lows at $67 reflect fears.....

by NATALIE SPENCER 30/09/2025 21

Supply Constraints Favor Competitors

Novo’s P/E below its 10-year average and strong